Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
141 shown of 2,431 total abstracts
  1. Abstract 40052026-09-01 · 14:15 CT · E450
    PACIFIC-893: Imfinzi (durvalumab) adjuvant in biliary tract
    N. Rizvi, P. Schmid, J. Brahmer · Massachusetts General Hospital
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  2. Abstract 93272026-09-03 · 20:45 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with NSCLC
    R. Herbst, C. Saura, N. Rizvi · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  3. Abstract 11542026-09-05 · 21:00 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for TNBC: KEYNOTE-570
    R. Herbst, J. Brahmer, S. Antonia, et al. · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  4. Abstract 11772026-09-04 · 19:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-786
    F. Andre, S. Modi, S. Peters · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  5. Abstract 12692026-09-02 · 13:45 CT · S100A
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-448
    E. Winer, P. Schmid, H. Borghaei, et al. · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  6. Abstract 14852026-09-02 · 19:45 CT · S100A
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    S. Tolaney, M.C. Garassino, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  7. Abstract 92872026-09-02 · 15:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-767
    A. Spira, C. Saura · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 18952026-09-02 · 15:45 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    G. Curigliano, R. Herbst · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  9. Abstract 11772026-09-02 · 13:45 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    A. Spira, T. Mok · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  10. Abstract 67892026-09-01 · 21:15 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-106
    F. Andre, J. Cortes, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  11. Abstract 97452026-09-03 · 18:00 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-221 study)
    A. Spira, C. Robert, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  12. Abstract 12442026-09-03 · 13:45 CT · S100A
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-22
    C. Robert, J. Cortes, J. Brahmer, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  13. Abstract 10342026-09-02 · 15:00 CT · Hall B1
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-734
    J. Brahmer, A. Spira, E. Winer · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  14. Abstract 98672026-09-04 · 21:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-7
    M. Reck, T. Mok · Karolinska Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  15. Abstract 48062026-09-01 · 21:15 CT · S406
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    N. Rizvi, H. Rugo, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  16. Abstract 47502026-09-01 · 21:15 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-890
    E. Winer, C. Robert, S. Tolaney · National Cancer Center Japan
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  17. Abstract 46972026-09-01 · 20:45 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-857
    C. Robert, M.C. Garassino, S. Modi, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  18. Abstract 93552026-09-02 · 18:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-973
    L. Paz-Ares, R. Herbst, N. Rizvi, et al. · Karolinska Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 11192026-09-04 · 14:45 CT · S406
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-264
    J. Brahmer, E. Winer, H. Borghaei · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  20. Abstract 41962026-09-01 · 15:00 CT · S406
    Quality of life outcomes with Imfinzi in patients with biliary tract
    S. Tolaney, R. Herbst · Mayo Clinic
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  21. Abstract 61542026-09-02 · 14:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-517 study)
    A. Spira, M. Reck, J. Brahmer, et al. · Massachusetts General Hospital
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  22. Abstract 17122026-09-02 · 14:30 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with TNBC
    N. Rizvi, S. Tolaney, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  23. Abstract 13882026-09-05 · 20:30 CT · S100A
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    G. Curigliano, J. Brahmer, N. Rizvi · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  24. Abstract 94112026-09-01 · 14:30 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    J. Brahmer, R. Herbst, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  25. Abstract 40062026-09-01 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-425 study)
    G. Curigliano, S. Peters, H. Borghaei, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  26. Abstract 92252026-09-05 · 16:45 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-648
    C. Robert, N. Rizvi, S. Tolaney · Chinese University of Hong Kong
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 19822026-09-04 · 21:30 CT · E450
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-626
    S. Peters, M. Krop, F. Andre, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  28. Abstract 12862026-09-03 · 21:00 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-546
    H. Borghaei, M.C. Garassino, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  29. Abstract 98352026-09-02 · 15:45 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-852
    S. Modi, M. Krop, N. Rizvi, et al. · National Cancer Center Japan
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  30. Abstract 69452026-09-04 · 13:00 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-939
    M. Reck, F. Andre, S. Peters, et al. · Massachusetts General Hospital
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  31. Abstract 16022026-09-04 · 20:15 CT · Arie Crown Theater
    IMpower-997: Tecentriq (atezolizumab) 1L in TNBC
    N. Rizvi, R. Herbst, H. Borghaei, et al. · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  32. Abstract 90762026-09-03 · 13:45 CT · Arie Crown Theater
    FLAURA-462: Tagrisso (osimertinib) 1L in NSCLC
    H. Borghaei, P. Schmid · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  33. Abstract 91162026-09-05 · 21:00 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    E. Winer, J. Brahmer, S. Peters · Royal Marsden Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  34. Abstract 62632026-09-01 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-22 study)
    H. Rugo, C. Robert, N. Rizvi, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  35. Abstract 53972026-09-02 · 15:45 CT · E450
    Long-term follow-up of Lynparza maintenance for prostate: OlympiA-41
    C. Saura, M.C. Garassino, T. Mok · Royal Marsden Hospital
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  36. Abstract 17652026-09-05 · 21:00 CT · S100A
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-438 study)
    A. Spira, G. Curigliano, M. Krop, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  37. Abstract 91232026-09-05 · 20:15 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-297
    A. Spira, S. Modi, H. Rugo · Stanford Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  38. Abstract 99972026-09-02 · 13:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-383 study)
    H. Borghaei, S. Antonia · Karolinska Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  39. Abstract 47322026-09-02 · 15:15 CT · S100A
    EV-364: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    M. Reck, H. Borghaei, C. Saura · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  40. Abstract 49942026-09-02 · 14:45 CT · Arie Crown Theater
    CheckMate-721: Opdivo (nivolumab) adjuvant in HCC
    T. Mok, P. Schmid, J. Cortes, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  41. Abstract 16582026-09-02 · 21:15 CT · S100A
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    S. Antonia, R. Herbst, F. Andre · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  42. Abstract 46592026-09-04 · 20:00 CT · S100A
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-577 study)
    L. Paz-Ares, H. Rugo · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  43. Abstract 97532026-09-01 · 18:15 CT · S406
    FLAURA-132: Tagrisso (osimertinib) 1L in NSCLC
    M. Krop, E. Winer, G. Curigliano, et al. · Mayo Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  44. Abstract 58842026-09-02 · 19:30 CT · E450
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-654 study)
    S. Peters, N. Rizvi, P. Schmid · Mayo Clinic
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  45. Abstract 90922026-09-01 · 21:00 CT · E450
    Long-term follow-up of Imfinzi 3L+ for NSCLC: PACIFIC-519
    A. Spira, T. Mok, M. Reck · Royal Marsden Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  46. Abstract 91332026-09-03 · 21:30 CT · Arie Crown Theater
    Quality of life outcomes with Tagrisso in patients with NSCLC
    F. Andre, M.C. Garassino, J. Cortes, et al. · Mayo Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  47. Abstract 57522026-09-02 · 13:30 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-639
    J. Brahmer, N. Rizvi, S. Modi, et al. · Royal Marsden Hospital
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  48. Abstract 96182026-09-05 · 20:30 CT · S100A
    PACIFIC-106: Imfinzi (durvalumab) 3L+ in SCLC
    S. Antonia, T. Mok, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  49. Abstract 47482026-09-02 · 21:00 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in HCC
    M.C. Garassino, M. Reck, S. Modi, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  50. Abstract 43872026-09-05 · 21:45 CT · S100A
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    T. Mok, G. Curigliano, P. Schmid, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  51. Abstract 40912026-09-04 · 21:15 CT · Hall B1
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    L. Paz-Ares, S. Tolaney, S. Peters, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  52. Abstract 11082026-09-04 · 18:45 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-432 study)
    M.C. Garassino, M. Krop, A. Spira · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  53. Abstract 64972026-09-05 · 20:15 CT · S406
    KEYNOTE-424: Keytruda (pembrolizumab) 3L+ in RCC
    F. Andre, H. Borghaei, T. Mok, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  54. Abstract 93252026-09-03 · 20:30 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for NSCLC: KEYNOTE-83
    N. Rizvi, M.C. Garassino, J. Brahmer · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  55. Abstract 97092026-09-05 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-380 study)
    G. Curigliano, H. Borghaei, R. Herbst, et al. · Royal Marsden Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  56. Abstract 96392026-09-02 · 14:30 CT · S100A
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    G. Curigliano, S. Modi, F. Andre, et al. · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  57. Abstract 15902026-09-02 · 16:45 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-904 study)
    S. Antonia, M.C. Garassino, S. Tolaney · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  58. Abstract 16742026-09-03 · 20:30 CT · S100A
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-158
    R. Herbst, M.C. Garassino, J. Brahmer, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  59. Abstract 18422026-09-05 · 20:00 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-569 study)
    J. Brahmer, T. Mok, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  60. Abstract 93682026-09-01 · 21:30 CT · S100A
    Long-term follow-up of Tecentriq maintenance for NSCLC: IMpower-557
    A. Spira, J. Cortes, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  61. Abstract 96702026-09-04 · 19:30 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-790
    C. Saura, S. Antonia, T. Mok · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  62. Abstract 42562026-09-04 · 15:15 CT · E450
    Long-term follow-up of Tecentriq 1L for HCC: IMpower-345
    J. Cortes, S. Tolaney, P. Schmid · Cleveland Clinic
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  63. Abstract 45482026-09-01 · 18:30 CT · S100A
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-275 study)
    H. Borghaei, M.C. Garassino, C. Robert · National Cancer Center Japan
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  64. Abstract 15762026-09-04 · 19:00 CT · S100A
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    M.C. Garassino, C. Robert, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  65. Abstract 97752026-09-04 · 16:45 CT · S406
    FLAURA-118: Tagrisso (osimertinib) maintenance in NSCLC
    C. Robert, C. Saura, H. Rugo, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  66. Abstract 41422026-09-02 · 16:00 CT · Arie Crown Theater
    Quality of life outcomes with Tecentriq in patients with HCC
    F. Andre, J. Cortes, M.C. Garassino · MD Anderson Cancer Center
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  67. Abstract 99252026-09-03 · 16:15 CT · E450
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-656 study)
    A. Spira, S. Tolaney, M.C. Garassino, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumMelanoma📄🖼️
  68. Abstract 14752026-09-05 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-288 study)
    A. Spira, T. Mok, L. Paz-Ares · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  69. Abstract 52332026-09-03 · 19:30 CT · S406
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-443
    N. Rizvi, A. Spira, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  70. Abstract 11112026-09-04 · 13:15 CT · Hall B1
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    N. Rizvi, M.C. Garassino, G. Curigliano · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  71. Abstract 99532026-09-01 · 18:30 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-764 study)
    M.C. Garassino, J. Cortes, F. Andre, et al. · National Cancer Center Japan
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  72. Abstract 13882026-09-01 · 18:30 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with TNBC
    N. Rizvi, T. Mok · Stanford Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  73. Abstract 17932026-09-03 · 14:30 CT · E450
    PALOMA-622: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    G. Curigliano, M. Krop · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  74. Abstract 46752026-09-01 · 14:30 CT · S406
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-762 study)
    C. Saura, N. Rizvi, M. Krop · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  75. Abstract 98352026-09-05 · 15:15 CT · Hall B1
    IMpower-660: Tecentriq (atezolizumab) adjuvant in NSCLC
    H. Rugo, T. Mok · University of Chicago
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  76. Abstract 95302026-09-03 · 16:30 CT · Arie Crown Theater
    Quality of life outcomes with Imfinzi in patients with SCLC
    L. Paz-Ares, S. Antonia, M. Reck, et al. · Karolinska Institute
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  77. Abstract 10372026-09-02 · 15:15 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-691
    T. Mok, M.C. Garassino, S. Antonia, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  78. Abstract 12672026-09-04 · 18:30 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-48
    J. Brahmer, P. Schmid, J. Cortes, et al. · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  79. Abstract 93492026-09-01 · 21:45 CT · S406
    PACIFIC-116: Imfinzi (durvalumab) neoadjuvant in SCLC
    C. Saura, M.C. Garassino, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  80. Abstract 19182026-09-03 · 16:45 CT · E450
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-953 study)
    P. Schmid, R. Herbst, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  81. Abstract 49082026-09-02 · 14:15 CT · S406
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-421 study)
    M.C. Garassino, A. Spira, M. Krop, et al. · Karolinska Institute
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  82. Abstract 13512026-09-05 · 14:45 CT · E450
    MONARCH-669: Verzenio (abemaciclib) 1L in HR+ breast cancer
    R. Herbst, G. Curigliano, J. Cortes · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  83. Abstract 57172026-09-03 · 16:45 CT · Hall B1
    Long-term follow-up of Lynparza 1L for prostate: OlympiA-804
    G. Curigliano, H. Rugo, M. Krop · University of Chicago
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  84. Abstract 12582026-09-02 · 13:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-321
    M.C. Garassino, E. Winer, S. Peters, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  85. Abstract 91032026-09-03 · 18:30 CT · Hall B1
    FLAURA-790: Tagrisso (osimertinib) adjuvant in NSCLC
    J. Brahmer, N. Rizvi, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  86. Abstract 13742026-09-01 · 20:45 CT · E450
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-220
    R. Herbst, L. Paz-Ares · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  87. Abstract 19552026-09-05 · 18:15 CT · E450
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-971
    S. Modi, A. Spira, L. Paz-Ares, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  88. Abstract 15442026-09-04 · 19:00 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-446
    E. Winer, M. Krop · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  89. Abstract 18652026-09-03 · 16:30 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-616 study)
    R. Herbst, S. Tolaney, S. Peters · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  90. Abstract 45872026-09-05 · 18:00 CT · S406
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-41 study)
    S. Modi, S. Tolaney, J. Cortes · Massachusetts General Hospital
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  91. Abstract 91262026-09-02 · 20:15 CT · Arie Crown Theater
    KEYNOTE-502: Keytruda (pembrolizumab) neoadjuvant in NSCLC
    H. Borghaei, P. Schmid · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  92. Abstract 46472026-09-02 · 19:30 CT · S406
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-363 study)
    M. Reck, H. Rugo, M.C. Garassino · Dana-Farber Cancer Institute
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  93. Abstract 10262026-09-05 · 19:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-789
    F. Andre, C. Saura, T. Mok · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  94. Abstract 14382026-09-05 · 15:45 CT · E450
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    H. Rugo, L. Paz-Ares, P. Schmid, et al. · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  95. Abstract 61412026-09-03 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-876
    L. Paz-Ares, C. Saura, N. Rizvi · Massachusetts General Hospital
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  96. Abstract 44132026-09-05 · 16:45 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-448 study)
    P. Schmid, C. Saura, T. Mok · Institut Gustave Roussy
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  97. Abstract 49122026-09-02 · 21:15 CT · E450
    ASCENT-563: Trodelvy (sacituzumab govitecan) 2L in urothelial carcinoma
    L. Paz-Ares, S. Modi, H. Rugo, et al. · Massachusetts General Hospital
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  98. Abstract 19442026-09-05 · 13:15 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with TNBC
    F. Andre, P. Schmid, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  99. Abstract 11112026-09-05 · 20:45 CT · S100A
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-978
    N. Rizvi, F. Andre, A. Spira, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  100. Abstract 10382026-09-05 · 13:15 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-57 study)
    C. Saura, F. Andre, J. Brahmer, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  101. Abstract 96492026-09-05 · 13:00 CT · Hall B1
    KEYNOTE-957: Keytruda (pembrolizumab) adjuvant in SCLC
    H. Borghaei, J. Cortes, S. Tolaney · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  102. Abstract 60892026-09-05 · 18:45 CT · S406
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    T. Mok, P. Schmid · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  103. Abstract 90662026-09-04 · 21:30 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    M. Krop, N. Rizvi, S. Modi, et al. · Royal Marsden Hospital
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  104. Abstract 19132026-09-01 · 21:30 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-51
    M.C. Garassino, S. Peters, S. Modi, et al. · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  105. Abstract 17672026-09-01 · 21:00 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-701
    M.C. Garassino, J. Brahmer, T. Mok · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  106. Abstract 97062026-09-01 · 21:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-833 study)
    F. Andre, M.C. Garassino, M. Reck, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  107. Abstract 99542026-09-05 · 15:30 CT · Arie Crown Theater
    KEYNOTE-490: Keytruda (pembrolizumab) 3L+ in metastatic melanoma
    J. Cortes, H. Rugo, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumMelanoma📄🖼️
  108. Abstract 96762026-09-04 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-308 study)
    T. Mok, M.C. Garassino · Peter MacCallum Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  109. Abstract 93752026-09-03 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-440
    E. Winer, F. Andre, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  110. Abstract 14792026-09-03 · 16:00 CT · S406
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-546
    M. Reck, H. Rugo, T. Mok · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  111. Abstract 42642026-09-04 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy maintenance for urothelial carcinoma: ASCENT-720
    M. Reck, S. Antonia · Institut Gustave Roussy
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  112. Abstract 43482026-09-03 · 13:45 CT · S100A
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-532
    C. Saura, J. Cortes, C. Robert, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  113. Abstract 97642026-09-01 · 19:45 CT · S100A
    Quality of life outcomes with Opdivo in patients with NSCLC
    M. Reck, M.C. Garassino, M. Krop · Chinese University of Hong Kong
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  114. Abstract 40702026-09-03 · 21:00 CT · E450
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-477 study)
    M. Krop, N. Rizvi, A. Spira · Cleveland Clinic
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  115. Abstract 92962026-09-04 · 19:30 CT · S406
    FLAURA-903: Tagrisso (osimertinib) maintenance in NSCLC
    S. Tolaney, M.C. Garassino, S. Peters · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  116. Abstract 16462026-09-03 · 21:15 CT · Arie Crown Theater
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    J. Cortes, R. Herbst, J. Brahmer · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  117. Abstract 47282026-09-04 · 16:30 CT · S100A
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-756 study)
    T. Mok, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  118. Abstract 14842026-09-05 · 21:15 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-853
    S. Antonia, N. Rizvi, A. Spira · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  119. Abstract 41692026-09-01 · 21:00 CT · S100A
    EV-844: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    C. Robert, R. Herbst, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  120. Abstract 40692026-09-05 · 18:30 CT · S406
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-640 study)
    T. Mok, M.C. Garassino, F. Andre · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  121. Abstract 46972026-09-05 · 19:30 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    N. Rizvi, L. Paz-Ares, M.C. Garassino, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  122. Abstract 46902026-09-02 · 20:00 CT · S406
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-298 study)
    C. Saura, M. Krop · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  123. Abstract 56902026-09-04 · 21:30 CT · E450
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-770 study)
    S. Peters, H. Rugo, A. Spira, et al. · Massachusetts General Hospital
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  124. Abstract 19862026-09-03 · 19:00 CT · S100A
    PALOMA-758: Ibrance (palbociclib) maintenance in HR+ breast cancer
    L. Paz-Ares, M. Krop · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  125. Abstract 59632026-09-01 · 16:45 CT · E450
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-94 study)
    N. Rizvi, S. Antonia, J. Cortes, et al. · Mayo Clinic
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  126. Abstract 97502026-09-05 · 21:45 CT · S406
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-695 study)
    H. Borghaei, M. Krop, T. Mok · Chinese University of Hong Kong
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  127. Abstract 19342026-09-04 · 20:15 CT · Arie Crown Theater
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    J. Brahmer, R. Herbst, C. Robert, et al. · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  128. Abstract 98712026-09-02 · 19:15 CT · S406
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-642
    H. Borghaei, J. Brahmer, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  129. Abstract 18972026-09-04 · 18:30 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-990
    A. Spira, S. Antonia · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  130. Abstract 97922026-09-05 · 13:00 CT · S406
    Quality of life outcomes with Enhertu in patients with NSCLC
    J. Cortes, P. Schmid, C. Robert, et al. · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  131. Abstract 41792026-09-03 · 13:00 CT · Hall B1
    ASCENT-264: Trodelvy (sacituzumab govitecan) maintenance in urothelial carcinoma
    N. Rizvi, S. Tolaney, C. Saura, et al. · Institut Gustave Roussy
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  132. Abstract 13102026-09-04 · 15:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-139
    F. Andre, M. Krop, S. Tolaney, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  133. Abstract 55172026-09-03 · 14:15 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-705
    M. Krop, J. Cortes, T. Mok · Chinese University of Hong Kong
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  134. Abstract 95262026-09-01 · 15:45 CT · E450
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-290
    C. Saura, S. Tolaney · Chinese University of Hong Kong
    Clinical Science SymposiumMelanoma📄🖼️
  135. Abstract 94952026-09-05 · 19:30 CT · Hall B1
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-462
    A. Spira, R. Herbst, J. Brahmer, et al. · Karolinska Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  136. Abstract 100362026-09-02 · 19:00 CT · S100A
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-694
    P. Schmid, M. Reck, H. Borghaei, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumMelanoma📄🖼️
  137. Abstract 47662026-09-02 · 15:15 CT · E450
    PACIFIC-514: Imfinzi (durvalumab) adjuvant in biliary tract
    H. Rugo, S. Peters · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  138. Abstract 99962026-09-03 · 15:15 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-352
    N. Rizvi, S. Peters, S. Modi · Karolinska Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  139. Abstract 95962026-09-02 · 18:30 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-95
    H. Rugo, T. Mok, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  140. Abstract 95242026-09-03 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-963 study)
    M.C. Garassino, J. Cortes, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  141. Abstract 19842026-09-01 · 14:00 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-920
    R. Herbst, J. Brahmer, M.C. Garassino, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.